Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Financial Officer | June 03, 2024 | June 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date June 03, 2024 · Filed June 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,000 |
Reported balance
After 2024-06-03 transaction · row 1
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 16,000 · Balance 16,000 F1: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2034-06-02 | Direct | 75,000 |
Reported balance
After 2024-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-03 · Grant · Acquired 75,000 · Balance 75,000 F3: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
F2: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date.
F3: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2024 Filed Jun 5, 2024 21:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-24-015622 · form4-06052024_090604.xml · derivative · entry 2 Kama Gulsen · CIK 0001991106 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-02 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015622 · form4-06052024_090604.xml · nonDerivative · entry 1 Kama Gulsen · CIK 0001991106 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · shares: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 21:21 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 106,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050184 · doc4.xml · derivative · entry 1 Kama Gulsen · CIK 0001991106 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires 2033-09-18 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest and become exercisable on September 11, 2024, and the remaining shares shall vest in a series of 36 successive equal monthly installments measured from September 11, 2024, subject to Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan, as amended) through each such applicable vesting date and the terms of the Company's 2020 Inducement Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.